SCNI
Scinai Immunotherapeutics LtdKey Statistics
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd is a cutting-edge biotechnology company specializing in the development of innovative immunotherapy solutions aimed at treating cancer and autoimmune disorders. Utilizing its proprietary immune modulation platform, Scinai is advancing a robust clinical pipeline that focuses on delivering transformative therapies to improve patient outcomes. With a highly experienced leadership team and a commitment to rigorous research, the company is well-positioned to capitalize on the growing demand for advanced immunotherapeutics in the global healthcare landscape. Strategic partnerships further enhance Scinai's potential for significant growth, establishing it as a key player in the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | $1.31M |
| Gross Profit (TTM) | $-2.65M |
| EBITDA | $-6.12M |
| Operating Margin | -702.00% |
| Return on Equity | -91.90% |
| Return on Assets | -37.60% |
| Revenue/Share (TTM) | $0.56 |
| Book Value | $0.71 |
| Price-to-Book | 1.01 |
| Price-to-Sales (TTM) | 1.74 |
| EV/Revenue | 6.66 |
| EV/EBITDA | 1.13 |
| Quarterly Earnings Growth (YoY) | 87.20% |
| Quarterly Revenue Growth (YoY) | 30.60% |
| Shares Outstanding | $3.54M |
| Float | $12.21B |
| % Insiders | 11.37% |
| % Institutions | 5.13% |
Historical Volatility
Volatility is currently expanding